Outcomes With Neoadjuvant Versus Adjuvant Chemotherapy For T1-2 Node Negative Triple Negative Breast Cancer.

1092 Background: Randomized studies have demonstrated that Neoadjuvant Chemotherapy (NAC) is equivalent to adjuvant chemotherapy (AdjC) in operable breast cancer (BC). However, the differential impact of NAC vs AdjC on outcomes in various BS subtypes is not known. Specifically, the impact of AdjC vs NAC BC outcomes in small (T1-2) clinically node negative (NN) triple negative breast cancer (TNBC) is not known. Aim: To evaluate the impact of NAC vs. AdjC on BC recurrence and RFS in NN T1-2 TNBC utilizing data from a prospective registry. Methods: 316 stage I-III TNBC patients enrolled in a multisite IRB approved registry between 2011 and 2014. Clinical, demographic, chemotherapy and recurrence information was collected. This study was restricted to analysis of registry participants with T1-2, NN disease. RFS was estimated according to the Kaplan-Meier method and compared among groups with log-rank statistic. Results: 146 patients with NN T1-2 TNBC enrolled on the registry since 2011. Patients underwent eit...